Skip to main content
. 2018 Jul;16(6):786–848. doi: 10.2174/1570159X16666180308161642

Fig. (3).

Fig. (3)

Chemical structures of A2AAR antagonists in clinical trails for PD treatment: SYN-115 or Tozadenant (11), KW-6002 or Istradefylline (12), ST1535 (13), ST4206 (14), BIIB014/V2006 (15), SCH-420814/MK-3814 or Preladenant (16), and V-81444 (17). The chemical structure of PBF-509 was not disclosed.